August 11, 2022
Safeguard Scientifics Announces Second Quarter 2022 Financial Results
August 02, 2022
SAFEGUARD SCIENTIFICS TO RELEASE SECOND QUARTER 2022 FINANCIAL RESULTS ON THURSDAY, AUGUST 11th
July 21, 2022
MediaMath Announces Two Executive-Level Hires
June 23, 2022
meQuilibrium Appoints Experience Design Expert Dustin DiTommaso as Chief Design Officer
June 14, 2022
Syapse and Pierian Announce Genomics Collaboration to Power Precision Oncology
June 01, 2022
Moxe Health Raises $30M Series B to Further Advance Interoperability
May 27, 2022
Syapse Unveils Two New Studies on Use of Machine Learning on Real-World Data to Identify and Treat Cancer With Precision at ASCO 2022
May 26, 2022
Prognos Health Enhances HCP Precision Marketing Suite with Planning Engine to Accelerate RWD Insights and Improve Health Outcomes
May 05, 2022
Safeguard Scientifics Announces First Quarter 2022 Financial Results
May 04, 2022
Almirall Deploys Aktana's Contextual Intelligence 360 to Optimize Customer Engagement
April 25, 2022
SAFEGUARD SCIENTIFICS TO RELEASE FIRST QUARTER 2022 FINANCIAL RESULTS ON THURSDAY, MAY 5th
April 21, 2022
MediaMath Executes Recapitalization Transaction, Strengthening Platform for the Future
March 31, 2022
Syapse Announces Changes to Board of Directors, Adding Michael Mentesana and Elevating Frank Williams to Chairman Role
March 22, 2022
Main Line Health Collaborates with Syapse, Bringing Clinical Trial Opportunities to Patients with Cancer in Philadelphia Region
March 21, 2022
SAFEGUARD SCIENTIFICS ANNOUNCES SHARE REPURCHASE PROGRAM
March 09, 2022
Safeguard Scientifics Announces Full Year And Fourth Quarter 2021 Financial Results
February 28, 2022
SAFEGUARD SCIENTIFICS TO RELEASE FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS ON WEDNESDAY, MARCH 9th
January 20, 2022
Syapse Extends Collaboration with Pfizer to Continue to Generate Real-World Evidence in Breast Cancer
January 10, 2022
MediaMath Appoints Neil Nguyen as Chief Executive Officer
January 04, 2022
Illumina and Syapse Partner on Research to Evaluate Large Panel Biomarker Testing Patterns Across US Community Oncology Practices